Literature DB >> 2764643

Brain distribution of idebenone and its effect on local cerebral glucose utilization in rats.

Y Nagai1, K Yoshida, S Narumi, S Tanayama, A Nagaoka.   

Abstract

To investigate the possible action sites of a cerebral metabolism activator, idebenone, (6-(10-hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone), its distribution in the brain and effect on local cerebral glucose utilization (LCGU) were studied in normal (WKY) and stroke-prone spontaneously hypertensive rats (SHRSP) with cerebrovascular lesions. 14C-Idebenone distributed rapidly into the brain after intravenous administration (10 mg/kg), and the total 14C contents in the brain at peak time corresponded to 0.45-0.56% of the dosages. An autoradiographic study showed that the 14C levels were higher in the white than in the gray matter. When 14C-idebenone was administered orally (100 mg/kg) and intraperitoneally (30 mg/kg), the total 14C levels were not markedly different among the brain regions of the rats. The concentration of unchanged idebenone was higher in the cerebral cortex, thalamus, and cerebellum than that in the other brain regions. Studies on LCGU demonstrated that idebenone (30 mg/kg/day, i.p., for 3 days) improved the reduction of LCGU in SHRSP with stroke, especially in the temporal cortex, thalamus dorsomedial nucleus, subthalamic nucleus, mamillary body, hippocampus dentate gyrus, caudate-putamen, inferior colliculus, and cerebellar nucleus. Based on these results, possible action sites of idebenone for its main pharmacologic effects are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2764643     DOI: 10.1016/0167-4943(89)90008-3

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  7 in total

1.  Idebenone inhibition of glutamate release from rat cerebral cortex nerve endings by suppression of voltage-dependent calcium influx and protein kinase A.

Authors:  Yi Chang; Yu-Wan Lin; Su-Jane Wang
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-05-04       Impact factor: 3.000

Review 2.  Clinical pharmacokinetics of drugs for Alzheimer's disease.

Authors:  L Parnetti
Journal:  Clin Pharmacokinet       Date:  1995-08       Impact factor: 6.447

Review 3.  Idebenone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in age-related cognitive disorders.

Authors:  J C Gillis; P Benefield; D McTavish
Journal:  Drugs Aging       Date:  1994-08       Impact factor: 3.923

Review 4.  Idebenone and neuroprotection: antioxidant, pro-oxidant, or electron carrier?

Authors:  Sausan Jaber; Brian M Polster
Journal:  J Bioenerg Biomembr       Date:  2014-09-28       Impact factor: 2.945

5.  Evaluating the therapeutic potential of idebenone and related quinone analogues in Leber hereditary optic neuropathy.

Authors:  Patrick Yu-Wai-Man; Devorah Soiferman; David G Moore; Florence Burté; Ann Saada
Journal:  Mitochondrion       Date:  2017-01-16       Impact factor: 4.160

Review 6.  Idebenone: When an antioxidant is not an antioxidant.

Authors:  Nuri Gueven; Pranathi Ravishankar; Rajaraman Eri; Emma Rybalka
Journal:  Redox Biol       Date:  2020-11-25       Impact factor: 11.799

7.  Idebenone Regulates Aβ and LPS-Induced Neurogliosis and Cognitive Function Through Inhibition of NLRP3 Inflammasome/IL-1β Axis Activation.

Authors:  Hyun-Ju Lee; Jin-Hee Park; Hyang-Sook Hoe
Journal:  Front Immunol       Date:  2022-02-10       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.